Organic Chemical – Talk Bio

FDA Approves GSK’s Blenrep for Multiple Myeloma Treatment, Marking a Market Return

2 days ago talkbio0Tagged Approved, Blenrep, bortezomib, dexamethasone, Multiple Myeloma, SmithKline Beecham, United States Food and Drug Administration

Blenrep; GSK; FDA Approval; Multiple Myeloma; Bortezomib; Dexamethasone

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

3 days ago talkbio0Tagged Benefit, dealmaking, direct-to-consumer sales, drug price, gene therapy, Government, Hemlibra, Investments, manager, Manufacturing, Ocrevus, Pharmaceutical Services, pipeline, R&D, Roche (company), U.S., Vabysmo

Roche; drug pricing; US government; pharmacy benefit managers; direct-to-consumer sales; pipeline; dealmaking; US investment; manufacturing; gene therapy; R&D; Ocrevus; Hemlibra; Vabysmo

Flagship Pioneering Launches Expedition Medicines to Revolutionize Small-Molecule Drug Discovery with AI

3 days ago talkbio0Tagged AI drug discovery, covalent binding drugs, executive leadership, Expedition Medicines, Flagship, generative design, Lila Sciences, Small Molecule, startup

Flagship Pioneering; Expedition Medicines; AI drug discovery; small molecules; covalent binding drugs; Lila Sciences; biotech startup; generative design; executive leadership

Exelixis’ Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review

5 days ago talkbio0Tagged Colorectal Carcinoma, Exelixis, kinase inhibitor [EPC], Overall Survival, regorafenib, STELLAR-303 trial, Submission, Tecentriq, Third line treatment, United States Food and Drug Administration, zanzalintinib

Exelixis; zanzalintinib; kinase inhibitor; colorectal cancer; STELLAR-303 trial; Tecentriq; regorafenib; overall survival; third-line therapy; FDA submission

Roche’s Giredestrant Advances Oral SERD Debate at ESMO 2025

5 days ago talkbio0Tagged ER-Positive HER2-Negative Breast Cancer, ESMO, giredestrant, Oral SERD, Roche (company)

ESMO 2025; Giredestrant; Roche; Oral SERD; ER-Positive HER2-Negative Breast Cancer

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

5 days ago talkbio0Tagged Achieve Life Sciences, Approved, Chief Legal Officer, cytisine, Erik Atkisson, United States Food and Drug Administration

Achieve Life Sciences; Erik Atkisson; Chief Legal Officer; Cytisinicline; FDA Approval

FDA Approves Roche’s Biogen-Partnered Gazyva for Lupus Nephritis

6 days ago talkbio0Tagged Biogen, Gazyva, Lupus Nephritis, obinutuzumab, Roche (company), treatment approval, United States Food and Drug Administration

Gazyva; obinutuzumab; Roche; Biogen; FDA; lupus nephritis; treatment approval

Roche Claims Its SERD Is Most Potent After Positive Breast Cancer Data Presented at ESMO 2025

6 days ago talkbio0Tagged ER-positive, giredestrant, HER2-negative, Malignant neoplasm of breast, Oral SERD, Phase 3 trial, Progression-Free Survival, Roche (company), Selective Estrogen Receptor Down Regulator

Roche; SERD; giredestrant; breast cancer; ESMO 2025; progression-free survival; oral SERD; ER-positive; HER2-negative; phase 3 trial

CHMP Rejects Sanofi’s Rezurock Over Clinical Data Issues, Recommends Approval of BTK Inhibitor Wayrilz

1 week ago talkbio0Tagged Autoimmune thrombocytopenia, belumosudil, cGVHD, CHMP, chronic graft-versus-host disease, Clinical Data, Inosine Triphosphate, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, regulatory approval, Rezurock, Rilzabrutinib, sanofi, Wayrilz

Sanofi; CHMP; EMA; Rezurock; Wayrilz; Belumosudil; Rilzabrutinib; chronic graft-versus-host disease; cGVHD; immune thrombocytopenia; ITP; regulatory approval; clinical data

EMD Serono Joins TrumpRx in Affordability Push; Roche Launches DTC Program

1 week ago talkbio0Tagged Affordability, CNPV, direct-to-consumer sales, Ditiocarb, Electromechanical dissociation, Fertility Agents, Fertilization in Vitro, Pergoveris, Programs - Publication Format, Roche (company), serono, tariffs, TrumpRx, White House Executive Order

EMD Serono; TrumpRx; IVF therapies; affordability; fertility drugs; Direct-to-Consumer sales; Roche; DTC program; White House Executive Order; Section 232 tariffs; CNPV program; Pergoveris